Kayothera, Inc. (“Kayothera”), a preclinical therapeutics company developing first-in-class, small molecule inhibitors of the retinoid nuclear receptor pathway, today announces that it has selected ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback